Compared with platinum‐based chemotherapy, epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR–TKIs) significantly extend progression‐free survival (PFS) of advanced NSCLC patients harboring an activating mutation in EGFR.5 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.